Biomarker · Gene alteration

PDGFRA mutation

Activating PDGFRA mutations, notably exon 18 D842V, detected by sequencing of tumor tissue; used as a predictive marker for PDGFRA-selective inhibitors in gastrointestinal stromal tumor.

CI-BIO-00000051PDGFRA graph →NCIt C39718

Also calledPDGFRA D842V · PDGFRA exon 18 · PDGFRA-mutant

Derived

Associated cancers (2)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Gastrointestinal Stromal Tumor	8	7	—	1	0 / 4 / 2 / 2 / 0
Malignant Neoplasm	3	3	—	—	0 / 0 / 0 / 3 / 0

Derived

Drugs with predictive evidence (4)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
ImatinibSmall Molecule	6	—	6	B	0 / 6	Gastrointestinal Stromal Tumor, Malignant Neoplasm
SunitinibSmall Molecule	2	—	2	C	0 / 2	Gastrointestinal Stromal Tumor,

Curated evidence

Predictive evidence items (10)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PDGFRA D842V10
Crenolanib

Regulatory

Approvals mentioning the linked drugs (133)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfda

Clinical trials

Active trials (18)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 13 recruiting · 5 active phase 3 · 96 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–18 of 18 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07585266	A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)	recruiting	Phase 3

Literature

Linked publications (8)

Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–8 of 8 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
· J Clin Oncol · 2003 · PMID 14645423 · validated civic_curation pubmed
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
· J Clin Oncol · 2005 · PMID 15928335 · validated civic_curation pubmed
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
· J Clin Oncol · 2006 · PMID 16954519 · validated civic_curation pubmed
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
· Cancer Res Treat · 2016 · PMID 26130666 · validated

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Imatinib	US FDA	—	Efficacy supplement 2007-09-13 (see label)	approved	Sep 13, 2007	openfda
Imatinib	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib	US FDA	—	Efficacy supplement 2006-09-27 (see label)	approved	Sep 27, 2006	openfda
Imatinib	US FDA	—	Efficacy supplement 2005-10-20 (see label)	approved	Oct 20, 2005	openfda
Imatinib	US FDA	—	Efficacy supplement 2005-03-14 (see label)	approved	Mar 14, 2005	openfda
Imatinib	US FDA	—	Efficacy supplement 2003-12-08 (see label)	approved	Dec 8, 2003	openfda
Imatinib	US FDA	—	Efficacy supplement 2003-05-20 (see label)	approved	May 20, 2003	openfda
Imatinib	US FDA	—	Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.	approved	Apr 18, 2003	openfda
Imatinib	US FDA	Acute Lymphoblastic Leukemia	Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).	approved	Apr 18, 2003	openfda
Imatinib	US FDA	Chronic Eosinophilic Leukemia, Not Otherwise Specified	Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.	approved	Apr 18, 2003	openfda
Imatinib	US FDA	Malignant Gastrointestinal Stromal Tumor	Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).	approved	Apr 18, 2003	openfda
Imatinib	US FDA	Aggressive Systemic Mastocytosis	Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.	approved	Apr 18, 2003	openfda
Imatinib	US FDA	Myelodysplastic/Myeloproliferative Neoplasm	Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.	approved	Apr 18, 2003	openfda
Imatinib	US FDA	Acute Lymphoblastic Leukemia	Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2016-08-25 (see label)	approved	Aug 25, 2016	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2015-01-30 (see label)	approved	Jan 30, 2015	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2013-01-25 (see label)	approved	Jan 25, 2013	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2012-01-31 (see label)	approved	Jan 31, 2012	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2011-04-01 (see label)	approved	Apr 1, 2011	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2009-05-27 (see label)	approved	May 27, 2009	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2008-12-19 (see label)	approved	Dec 19, 2008	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2008-09-26 (see label)	approved	Sep 26, 2008	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2007-09-13 (see label)	approved	Sep 13, 2007	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2006-10-19 (see label)	approved	Oct 19, 2006	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2006-09-27 (see label)	approved	Sep 27, 2006	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2005-10-20 (see label)	approved	Oct 20, 2005	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2005-03-14 (see label)	approved	Mar 14, 2005	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2003-12-08 (see label)	approved	Dec 8, 2003	openfda
Imatinib Mesylate	US FDA	—	Efficacy supplement 2003-05-20 (see label)	approved	May 20, 2003	openfda
Imatinib Mesylate	US FDA	Chronic Eosinophilic Leukemia, Not Otherwise Specified	Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	Aggressive Systemic Mastocytosis	Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	Acute Lymphoblastic Leukemia	Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	Acute Lymphoblastic Leukemia	Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	Myelodysplastic/Myeloproliferative Neoplasm	Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	Malignant Gastrointestinal Stromal Tumor	Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).	approved	Apr 18, 2003	openfda
Imatinib Mesylate	US FDA	—	Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.	approved	Apr 18, 2003	openfda
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552892) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552906) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02539284) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532190) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 18, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd